

INDEX

BIO-SCIENCE LAW REVIEW

VOLUME 14

CONTENTS

Subject Index	i
Countries and Institutions	ii
Contributors	iii
Contributions	iii
Case List	iv

Subject Index

BIG DATA

'Mining for gold': capitalising on data to transform drug development (Editorial) 1 3

BIOSIMILARS

Amgen v Sandoz: US Appellate Court rules that the information exchange contemplated by the Biologics Price Competition and Innovation Act of 2009 is optional (Case Comment) 6 240

Importance of certainty in the regulation of biosimilars (Article) 6 211

COSMETIC PRODUCTS

Nanomaterials

Nanomaterials in the EU Cosmetic Products Regulation 1223/2009 (Article) 6 223

DATA PROTECTION

'Mining for gold': capitalising on data to transform drug development (Editorial) 1 3

Publication of clinical trial data by the European Medicines Agency (Article) 3 67

GM CROPS

Economic loss

GM v organic farming: *Marsh v Baxter* (Case Comment) 2 48

Environmental impact

Humming a different tune? Commercial cultivation of GM crops in Europe (Article) 5 185

HEALTHCARE

Enforceability of NICE guidance and guidelines (Article) 5 179

Evaluating NICE: good value for money? (Editorial) 3 63

INTELLECTUAL PROPERTY

Plant varieties

Intellectual property protection of new varieties of plants in Sub-Saharan Africa: overview of existing regimes (Article) 3 75, 4 130

Plant breeding innovations: free access but not access for free.

A new approach to facilitating FRAND licences for plant-related patents (Article) 4 123

MEDICINAL PRODUCTS

CJEU rules on the requirements for protecting carrier proteins using Supplementary Protection Certificates (SPCs) (Case Comment) 4 159

NAGOYA PROTOCOL

Restrictions governing international trade in genetic resources enter into force (Case Comment) 4 163

NANOMATERIALS

Cosmetic products

Nanomaterials in the EU Cosmetic Products Regulation 1223/2009 (Article) 6 223

PATENTS

Antibodies

Patent protection for antibodies: the evolving challenges (Article) 1 9

Divisional application

Poisonous divisionals: any end in sight? (Article) 2 40

Experimental use exemption

Going full circle: Bolar in Europe and the UPC (Article) 2 31

Gene patents

Isolated nucleic acid sequences patentable in Australia: *D'Arcy v Myriad Genetics Inc* (Case Comment) 2 43

Indirect infringement

Skinny labelling and indirect infringement – consider being proactive: *Novartis v Sun* (Case Comment) 3 115

Obviousness

LEO's patent not 'obvious to try' because there was 'no reasonably optimistic expectation' of success regarding the claimed invention (Case Comment) 6 243

Patentability

Broccoli and tomato: free or not free? Decisions G2/12 and G2/13 of the Enlarged Board of Appeal (Case Comment) 4 167

European Court of Justice refines the meaning of 'human embryo' (Case Comment) 3 102

Patent protection for antibodies: the evolving challenges (Article) 1 9

Plant breeding

Broccoli and tomato: free or not free? Decisions G2/12 and G2/13 of the Enlarged Board of Appeal (Case Comment) 4 167

Plant breeding innovations: free access but not access for free. A new approach to facilitating FRAND licences for plant-related patents (Article) 4 123

Supplementary Protection Certificates

Article 3(a) SPC Regulation – guidance on obtaining SPCs based on functional claims: *Lilly v HGS* (Case Comment) 1 25

CJEU rules again on combination SPCs – *Actavis v Boehringer* (Case Comment) 5 193

CJEU rules on the requirements for protecting carrier proteins using Supplementary Protection Certificates (SPCs) (Case Comment) 4 159

Meaning of ‘active ingredient’ for SPC protection is again uncertain: *Bayer CropScience AG* (Case 11/13) (Case Comment) 1 21

Supplementary Protection Certificates for biologicals: some guidance from *Pharmaq v Intervet* (Article) 5 179

Swiss form claims

English Court of Appeal rules on the construction of Swiss form patent claims in *Warner-Lambert v Actavis* (Case Comment) 5 201

Warner-Lambert v Actavis: the end of the beginning? (Article) 6 214

Warner-Lambert v Actavis: what are the limits of Swiss form claims? (Case Comment) 3 107

Transdermal patches

Novartis’ patent on a transdermal therapeutic system for the administration of rivastigmine found invalid, clearing the way to ‘generics’ to the Exelon Patch (Case Comment) 5 196

PHARMACEUTICAL PRODUCTS

Development

Evaluating NICE: good value for money? (Editorial) 3 63

‘Mining for gold’: capitalising on data to transform drug development (Editorial) 1 3

PLANT VARIETIES

Intellectual property protection of new varieties of plants in Sub-Saharan Africa: overview of existing regimes (Article) 3 75, 4 130

UPOV and the plant variety protection system: a case study of Colombia (Article) 6 234

TRADE SECRETS

Trade secrets: Council agrees general approach for trade secret proposal (Case Comment) 1 17

Countries and Institutions

AUSTRALIA

Biosimilars

Importance of certainty in the regulation of biosimilars (Article) 6 211

GM crops

GM v organic farming: *Marsh v Baxter* (Case Comment) 2 48

Patents

Isolated nucleic acid sequences patentable in Australia: *D’Arcy v Myriad Genetics Inc* (Case Comment) 2 43

COLOMBIA

Plant varieties

UPOV and the plant variety protection system: a case study of Colombia (Article) 6 234

COURT OF JUSTICE OF THE EUROPEAN UNION

CJEU rules again on combination SPCs – *Actavis v Boehringer* (Case Comment) 5 193

CJEU rules on the requirements for protecting carrier proteins using Supplementary Protection Certificates (SPCs) (Case Comment) 4 159

European Court of Justice refines the meaning of ‘human embryo’ (Case Comment) 3 102

Meaning of ‘active ingredient’ for SPC protection is again uncertain: *Bayer CropScience AG* (Case 11/13) (Case Comment) 1 21

EUROPEAN COUNCIL

Trade secrets: Council agrees general approach for trade secret proposal (Case Comment) 1 17

EUROPEAN FREE TRADE ASSOCIATION (EFTA) COURT

Supplementary protection certificates

Supplementary Protection Certificates for biologicals: some guidance from *Pharmaq v Intervet* (Article) 5 179

EUROPEAN PATENT OFFICE

Patentability

Broccoli and tomato: free or not free? Decisions G2/12 and G2/13 of the Enlarged Board of Appeal (Case Comment) 4 167

Patent protection for antibodies: the evolving challenges (Article) 1 9

EUROPEAN UNION

Cosmetic products

Nanomaterials in the EU Cosmetic Products Regulation 1223/2009 (Article) 6 223

Data protection

Publication of clinical trial data by the European Medicines Agency (Article) 3 67

GM crops

Humming a different tune? Commercial cultivation of GM crops in Europe (Article) 5 185

Nagoya Protocol

Restrictions governing international trade in genetic resources enter into force (Case Comment) 4 163

Nanomaterials

Nanomaterials in the EU Cosmetic Products Regulation 1223/2009 (Article) 6 223

Patents

Going full circle: Bolar in Europe and the UPC (Article) 2 31

Plant breeding innovations: free access but not access for free.

A new approach to facilitating FRAND licences for plant-related patents (Article) 4 123

Poisonous divisionals: any end in sight? (Article) 2 40

GERMANY

Patents

Going full circle: Bolar in Europe and the UPC (Article) 2 31

NETHERLANDS

Patents

Skinny labelling and indirect infringement – consider being proactive: *Novartis v Sun* (Case Comment) 3 115

SUB-SAHARAN AFRICA

Plant varieties

Intellectual property protection of new varieties of plants in Sub-Saharan Africa: overview of existing regimes (Article) 3 75, 4 130

UNIFIED PATENT COURT

Going full circle: Bolar in Europe and the UPC (Article) 2 31

UNITED KINGDOM**Healthcare**

Enforceability of NICE guidance and guidelines (Article) 5 179

Evaluating NICE: good value for money? (Editorial) 3 63

Patents

Article 3(a) SPC Regulation – guidance on obtaining SPCs based on functional claims: *Lilly v HGS* (Case Comment) 1 25

English Court of Appeal rules on the construction of Swiss form patent claims in *Warner-Lambert v Actavis* (Case Comment) 5 201

Going full circle: Bolar in Europe and the UPC (Article) 2 31

LEO's patent not 'obvious to try' because there was 'no reasonably optimistic expectation' of success regarding the claimed invention (Case Comment) 6 243

Novartis' patent on a transdermal therapeutic system for the administration of rivastigmine found invalid, clearing the way to 'generics' to the Exelon Patch (Case Comment) 5 196

Patent protection for antibodies: the evolving challenges (Article) 1 9

Warner-Lambert v Actavis: the end of the beginning? (Article) 6 214

Warner-Lambert v Actavis: what are the limits of Swiss form claims? (Case Comment) 3 107

Pharmaceutical products

Evaluating NICE: good value for money? (Editorial) 3 63

UNITED STATES**Biologics**

Amgen v Sandoz: US Appellate Court rules that the information exchange contemplated by the Biologics Price Competition and Innovation Act of 2009 is optional (Case Comment) 6 240

Contributors

Antcliff, Jenny (Case Comment) 1 25

Blakeney, Michael (Case Comment) 2 48

Bradbury, Simon (Book Review) 6 247

Carter, Ailsa (Article) 6 214; (Case Comment) 5 201

Cline, Helen (Editorials) 1 3, 3 63

Cohen, Liz (Article) 1 9

Dautlich, Marc (Editorial) 1 3

De Coster, Christoph (Article) 2 31

Duxbury, Pat (Case Comment) 5 196

Ellsmore, James (Case Comment) 2 43

England, Paul (Article) 2 31; (Case Comment) 1 21

Heimhalt, Diana (Article) 3 67

Hill, Christian (Article) 5 182

Hutchinson, Katie (Case Comment) 5 193

Inman, Paul (Article) 6 214; (Case Comment) 6 243

Jackson, Stuart (Case Comment) 3 107

Jose, Sherine (Article) 6 234

Kailasanath, Vinita (Case Comment) 6 240

Kempton, Luke (Case Comment) 5 201

Kock, Michael A (Article) 4 123; (Case Comment) 4 167

Kuipers, Gertjan (Case Comment) 3 115

Lee, Robert G (Article) 5 185

Lynch, Maevé (Case Comment) 3 102

Madar, Suzy (Article) 6 211

Maggs, Andrew (Case Comment) 6 243

Mahop, Marcelin Tonye (Article) 3 75, 4 130

Manheim, Bruce S (Case Comment) 4 163

Marsh, David (Case Comment) 6 240

Meade, Alexandra (Case Comment) 2 48

Mester, Gabor (Article) 2 40

Michel, Sara (Article) 2 40

Miles, John (Article) 5 179

Naylor, Tom (Case Comment) 2 43

O'Connell, Kim (Article) 6 211; (Case Comment) 2 43

O'Farrell, Jennifer (Case Comment) 4 159

Pears, Michael (Article) 5 179

Ramirez de la Piscina, Aratz (Article) 6 223

Ranson, Paul (Editorial) 3 63; (Article) 5 179

Rehmann, Wolfgang A (Article) 3 67

Reynolds, Laura (Case Comment) 5 193

Ribbons, Duncan (Case Comment) 3 102

Rieu, Vanessa (Article) 1 9

Roberts, Tim (Book Review) 2 57

Royle, Matthew (Article) 2 31

Shikoli, Aprinah Magarinah (Article) 3 75, 4 130

Tejan-Cole, Alhaji (Article) 3 75, 4 130

Ter Woort, Bertrand (Case Comment) 3 115

Watts, Jennifer (Case Comment) 1 17

Whitehead, Brian (Case Comment) 3 107

Contributions**EDITORIALS**

Evaluating NICE: good value for money? *Paul Ranson and Helen Cline* 3 63

'Mining for gold': capitalising on data to transform drug development *Helen Cline and Marc Dautlich* 1 3

ARTICLES

Enforceability of NICE guidance and guidelines

Paul Ranson and Christian Hill 5 179

Going full circle: Bolar in Europe and the UPC

Paul England, Matthew Royle and Christoph de Coster 2 31

Humming a different tune? Commercial cultivation of GM crops in Europe *Professor Robert G Lee* 5 185

Importance of certainty in the regulation of biosimilars

Kim O'Connell and Suzy Madar 6 211

Intellectual property protection of new varieties of plants in

Sub-Saharan Africa: overview of existing regimes

Marcelin Tonye Mahop, Aprinah Magarinah Shikoli

and Alhaji Tejan-Cole 3 75, 4 130

Nanomaterials in the EU Cosmetic Products Regulation 1223/2009

Aratz Ramirez de la Piscina 6 223

Patent protection for antibodies: the evolving challenges

Liz Cohen and Vanessa Rieu 1 9

Plant breeding innovations: free access but not access for free.

A new approach to facilitating FRAND licences for plant-related

patents *Michael A Kock* 4 123

Poisonous divisionals: any end in sight? *Dr Sara Michel*

and Dr Gabor Mester 2 40

Publication of clinical trial data by the European Medicines

Agency *Diana Heimhalt and Dr Wolfgang A Rehmann* 3 67

Supplementary Protection Certificates for biologics:

some guidance from *Pharmaq v Intervet*

John Miles and Michael Pears 5 179

UPOV and the plant variety protection system: a case study of

Colombia *Sherine Jose* 6 234

Warner-Lambert v Actavis: the end of the beginning?

Paul Inman and Ailsa Carter 6 214

CASE COMMENTS

Amgen v Sandoz: US Appellate Court rules that the information exchange contemplated by the Biologics Price Competition and Innovation Act of 2009 is optional *Vinita Kailasanath and Dr David Marsh* 6 240

Article 3(a) SPC Regulation – guidance on obtaining SPCs based on functional claims: *Lilly v HGS*

Dr Jenny Antcliff 1 25

Broccoli and tomato: free or not free? Decisions G2/12 and G2/13 of the Enlarged Board of Appeal *Michael A Kock* 4 167

- CJEU rules again on combination SPCs – *Actavis v Boehringer Katie Hutchinson and Laura Reynolds* 5 193
- CJEU rules on the requirements for protecting carrier proteins using Supplementary Protection Certificates (SPCs) *Jennifer O' Farrell* 4 159
- English Court of Appeal rules on the construction of Swiss form patent claims in *Warner-Lambert v Actavis Luke Kempton and Ailsa Carter* 5 201
- European Court of Justice refines the meaning of 'human embryo' *Duncan Ribbons and Maeve Lynch* 3 102
- GM v organic farming: *Marsh v Baxter Alexandra Meade and Michael Blakeney* 2 48
- Isolated nucleic acid sequences patentable in Australia: *D'Arcy v Myriad Genetics Inc Kim O' Connell, James Ellsmore and Tom Naylor* 2 43
- LEO's patent not 'obvious to try' because there was 'no reasonably optimistic expectation' of success regarding the claimed invention *Paul Inman and Andrew Maggs* 6 243
- Meaning of 'active ingredient' for SPC protection is again uncertain: *Bayer CropScience AG (Case 11/13) Paul England* 1 21
- Novartis' patent on a transdermal therapeutic system for the administration of rivastigmine found invalid, clearing the way to 'generics' to the Exelon Patch *Pat Duxbury* 5 196
- Restrictions governing international trade in genetic resources enter into force *Bruce S Manheim* 4 163
- Skinny labelling and indirect infringement – consider being proactive: *Novartis v Sun Gertjan Kuipers and Bertrand Ter Woort* 3 115
- Trade secrets: Council agrees general approach for trade secret proposal *Jennifer Watts* 1 17
- Warner-Lambert v Actavis*: what are the limits of Swiss form claims? *Dr Brian Whitehead and Stuart Jackson* 3 107

BOOK REVIEWS

- Intellectual Property Law of Plants (Mark D Janis, Herbert H Jervis and Richard C Peet) *Tim Roberts* 2 57
- Patent Term Extensions: USA, Japan, Germany, EU (Arne Markgraf, ed.) *Simon Bradbury* 6 247

Case List

- Actavis v Boehringer* (CJEU) Case C–577/13 12 March 2015 5 193
- Actavis v Sanofi* (CJEU) C–443/12 5 193
- Amgen Inc. v Sandoz Inc.* (United States) 2015 WL 1264756, *8–11 (N.D. Cal. Mar. 19, 2015), WL 4430108, *10–15 (Fed. Cir. July 21, 2015) 6 240

- Arne Forsgren v Österreichisches Patentamt* (CJEU) Case C–631/12 15 January 2015
- Association for Molecular Pathology v Myriad Genetics, Inc* (United States) 133 S. Ct. 2107 (2013) 2 45
- Bayer/CropScience AG* (CJEU) Case C–11/13 ECLI:EU:C:2014:2010 1 21
- Cancer Voices Australia v Myriad Genetics Inc* (Australia) (2013) 99 IPR 567 (15 February 2013) 2 43
- D'Arcy v Myriad Genetics Inc* (Australia) [2014] FCAFC 115 (5 September 2014) 2 43
- Eli Lilly and Company Ltd v Human Genome Sciences, Inc* [2014] EWHC 2404 (Pat) 18 July 2014 1 25
- Generics v Yeda and Teva* [2013] EWCA Civ 925 1 13
- Generics UK v Daichi* [2008] EWHC 1903 (Pat) 1 12
- Generics (UK) Ltd (t/a Mylan) v Warner-Lambert Company LLC* [2015] EWHC 2548 (Pat) 6 214
- Georgetown University v Octrooicentrum Nederland* (2013) WLR (D) 487 4 160
- GlaxoSmithKlein Biologicals SA and another v Comptroller-General of Patents, Designs and Trade Marks* (CJEU) Case C–210/13 14 November 2013 1 21, 4 161
- Hospira v Genentech* (No 1) [2014] EWHC 1094 (Pat) 6 219
- Hospira v Genentech* (No 3) [2015] EWHC 1796 (Pat) 6 219
- Hospira UK Limited v Genentech Inc*, Patents Court [2014] EWHC 1094 1 16
- International Stem Cell Corporation v Comptroller General* (CJEU) Case C–364/13 3 102
- Kirin-Amgen Inc. and others v Hoechst Marion Roussel Ltd and others* [2004] UKHL 46 1 12
- Marsh v Baxter* (Australia) [2014] WASC 187 2 48
- Massachusetts Institute of Technology (MIT)* (CJEU) Case C–431/04 EU: C:2006:291 1 22
- MedImmune Ltd v Novartis Pharmaceuticals UK Ltd* [2012] EWCA Civ 1234, [2013] RPC 27 1 13
- Neurim Pharmaceuticals* (CJEU) Case C–130/11 ECLR:EU:C:2013:762 1 23, 4 160
- Novartis AG v Sun Pharmaceutical Industries (Europe) BV* (Netherlands) Court of Appeal of The Hague 27 January 2015, IEF 14599 3 112, 3 115
- Oliver Brüstle v Greenpeace* (CJEU) Case C–34/10 3 102
- Pharmaq AS v Intervet International BV* (EFTA Court) Case E–16/14 9 April 2015 5 179
- Regeneron Pharmaceuticals Inc & Bayer AG v Genentech Inc* [2013] EWCA Civ 93 1 13
- Teva v LEO* [2015] EWCA Civ 779 6 243
- Warner-Lambert v Actavis* [2015] EWHC 72 (Pat), [2015] EWCA Civ 556 3 106, 5 201, 6 214